Solriamfetol
Brand Names: Sunosi
Methodology & AI Transparency ⓘ
Solriamfetol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage sunosi: is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) .
- 2 Real-world patient consensus: Real-world cohort score of 74% across 16 de-identified Solriamfetol entries.
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($31.2166/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Solriamfetol): nausea (12.9%), headache (11.5%), insomnia (7.2%).
Ask our AI Specialists anything about Solriamfetol
Solriamfetol Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage sunosi: is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI.
12.1 Mechanism of Action The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).
With Steady-state plasma equilibrium reached over 6–18 hour t½ intervals for Solriamfetol residence kinetics and ~95% systemic bioavailability (Solriamfetol) bioavailability, Solriamfetol undergoes predominantly hepatic biotransformation with renal elimination of polar solriamfetol conjugates and establishes therapeutic activity over maximum serum exposure occurs 2–5 hours after solriamfetol dosing.
Standard adult regimens span 75 mg/1 Tablet, Film Coated, 150 mg/1 Tablet, Film Coated. Prescribers screen specifically against history of severe allergic sensitivity to solriamfetol active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-05-05 solriamfetol labeling, while community micro-logs most frequently note nausea (12.9% of reports), headache (11.5% of reports), insomnia (7.2% of reports).
Concomitant MAOI therapy potentiates hazardous biogenic amine accumulation during Solriamfetol treatment.
Verify medication reconciliation lists so Solriamfetol is not inadvertently duplicated with another dopamine and norepinephrine reuptake inhibitor.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Solriamfetol active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-05-05 Solriamfetol labeling
Logged Side-Effect Incidence (16 Reports)
Solriamfetol Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Solriamfetol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a: What a 231-Participant Study Found A greater percentage of participants treated with solriamfetol achieved normal ESS scores (≤ 10) or clinically meaningful improvements on the ESS compared with those receiving placebo. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine • 2021-04-01 • Phase III Randomized Trial | N = 231 | 88/100 | PMID 33226332 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term study of the safety and maintenance of efficacy of solriamfetol This study demonstrated long-term maintenance of efficacy of solriamfetol under open-label and gold-standard blind, compared against a dummy pill (placebo) conditions. Sleep • 2020-02-13 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 31691827 ↗ |
| Can This Approach Help? Inside the Latest Research on Determination of thresholds for minimally important difference and clinically Minimally important difference and clinically important response estimates for the FOSQ-10 for adults with excessive daytime sleepiness in narcolepsy or obstructive sleep apnea will be helpful for interpreting changes over... Sleep & breathing = Schlaf & Atmung • 2021-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33394323 ↗ |
Solriamfetol Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $31.2166/unit (~$936.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Solriamfetol Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Solriamfetol RxNorm Concept ID | 2121756 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $31.2166 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Solriamfetol Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Solriamfetol: FDA labeling (2026-05-05, NDC 81968-350), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Solriamfetol community threads and patient logs by age, biological sex, dosage, and treatment duration.